Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Oryzon Genomics SA ( (ES:ORY) ) has issued an update.
Oryzon Genomics reported a net loss of €1.7M for Q1 2025, aligning with its long-term product development strategy. The company strengthened its financial position with a €30M capital increase and is preparing for a Phase III trial of vafidemstat for Borderline Personality Disorder. Additionally, Oryzon is advancing its oncology trials and expects a significant grant to boost its therapeutic development programs.
More about Oryzon Genomics SA
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company and a European leader in the field of epigenetics. The company focuses on developing therapies for psychiatric disorders and oncology, with a market emphasis on personalized medicine approaches.
YTD Price Performance: 96.07%
Average Trading Volume: 1,477,354
Technical Sentiment Signal: Buy
Current Market Cap: €212.8M
See more insights into ORY stock on TipRanks’ Stock Analysis page.